Intensity Therapeutics Inc. (NASDAQ:INTS) Receives Average Rating of “Moderate Buy” from Analysts

Intensity Therapeutics Inc. (NASDAQ:INTS) has received a consensus recommendation of “Moderate Buy” from the five brokerages that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $7.00.

Several analysts have recently weighed in on the company. Citigroup restated a “buy” rating on shares of Intensity Therapeutics in a report on Tuesday, August 11th. Weiss Ratings restated a “sell (e+)” rating on shares of Intensity Therapeutics in a research report on Tuesday, July 21st. HC Wainwright lifted their price target on shares of Intensity Therapeutics from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Finally, Benchmark reissued a “speculative buy” rating on shares of Intensity Therapeutics in a research note on Wednesday, May 20th.

Intensity Therapeutics Stock Up 2.5%

NASDAQ INTS opened at $4.10 on Friday. Intensity Therapeutics has a fifty-two week low of $3.51 and a fifty-two week high of $43.50. The business has a fifty day moving average price of $4.40 and a two-hundred day moving average price of $5.05. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.00 and a quick ratio of 5.00. The stock has a market capitalization of $13.37 million, a PE ratio of -1.15 and a beta of 2.76.

Intensity Therapeutics (NASDAQ:INTS) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.24). Equities analysts expect that Intensity Therapeutics will post -2.64 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Intensity Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC bought a new position in Intensity Therapeutics during the 4th quarter worth approximately $26,000. Corient Private Wealth LLC bought a new stake in shares of Intensity Therapeutics in the 4th quarter valued at $41,000. State Street Corp increased its position in shares of Intensity Therapeutics by 839.3% during the fourth quarter. State Street Corp now owns 136,200 shares of the company’s stock worth $56,000 after buying an additional 121,700 shares during the period. Mesirow Financial Investment Management Inc. raised its stake in Intensity Therapeutics by 25.5% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock worth $103,000 after buying an additional 51,000 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in Intensity Therapeutics by 77.8% during the fourth quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock worth $189,000 after buying an additional 201,357 shares during the last quarter. 3.74% of the stock is owned by institutional investors and hedge funds.

About Intensity Therapeutics

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.